Skip to main content
main-content

21.01.2017 | Original Article | Ausgabe 3/2017

Immunologic Research 3/2017

Glycyrrhizin ameliorates experimental colitis through attenuating interleukin-17-producing T cell responses via regulating antigen-presenting cells

Zeitschrift:
Immunologic Research > Ausgabe 3/2017
Autoren:
Xiangyu Chen, Dai Fang, Lingyun Li, Liyong Chen, Qirui Li, Feili Gong, Min Fang
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s12026-017-8894-2) contains supplementary material, which is available to authorized users.

Abstract

Glycyrrhizin, a component of Chinese medicine licorice root, has the ability to inhibit the functions of high-mobility group box 1 (HMGB1). While glycyrrhizin is known to have anti-inflammatory activities, the underlying mechanisms by which glycyrrhizin inhibits inflammation during the development of trinitrobenzenesulfonic acid (TNBS)-induced experimental colitis are not well understood. This study systemically examined the regulatory effects of glycyrrhizin on inflammatory response in TNBS-induced murine colitis and explored the potential mechanisms involved in this process. We reported that glycyrrhizin treatment ameliorated colitis and decreased the production of inflammatory mediators HMGB1, IFN-γ, IL-6, TNF-α, and IL-17. In addition, glycyrrhizin regulated responses of dendritic cells (DCs) and macrophages during the development of colitis. Furthermore, administration of glycyrrhizin suppressed the proliferation of Th17 cells in colitis. Moreover, the ability of DCs and macrophages to induce the differentiation of Th17 cells was enhanced in presence of HMGB1, which was inhibited by glycyrrhizin. These results demonstrated that glycyrrhizin alleviated colitis by inhibiting the promotive effect of HMGB1 on DC/macrophage-mediated Th17 proliferation. In conclusion, HMGB1 plays an important role in the development of colitis. As an inhibitor of HMGB1, glycyrrhizin might be a novel therapy for colitis.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
High resolution image (TIFF 522 kb)
12026_2017_8894_MOESM1_ESM.tif
High resolution image (TIFF 286 kb)
12026_2017_8894_MOESM2_ESM.tif
High resolution image (TIFF 404 kb)
12026_2017_8894_MOESM3_ESM.tif
High resolution image (TIFF 1394 kb)
12026_2017_8894_MOESM4_ESM.tif
High resolution image (TIFF 882 kb)
12026_2017_8894_MOESM5_ESM.tif
High resolution image (TIFF 276 kb)
12026_2017_8894_MOESM6_ESM.tif
High resolution image (TIFF 1710 kb)
12026_2017_8894_MOESM7_ESM.tif
High resolution image (TIFF 670 kb)
12026_2017_8894_MOESM8_ESM.tif
High resolution image (TIFF 618 kb)
12026_2017_8894_MOESM9_ESM.tif
High resolution image (TIFF 761 kb)
12026_2017_8894_MOESM10_ESM.tif
High resolution image (TIFF 1316 kb)
12026_2017_8894_MOESM11_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 3/2017

Immunologic Research 3/2017 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet HNO

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update HNO und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise